T-wave alternans phase reversal detection in implantable cardiac monitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing T-wave alternans (TWA) in clinical settings are complex and not suitable for implantable medical devices, limiting their ability to monitor patients at risk for ventricular arrhythmias and sudden cardiac death.
Innovation Solution
An implantable medical device (IMD) system that dynamically monitors TWA using EGM signals, incorporating an R-wave detector, EGM sense amplifier, signal conditioning module, and microprocessor to perform TWA assessment, including phase reversal detection, and communicates with external systems for data analysis and therapy delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If FFT method is used for frequency domain analysis of T-waves, then TWA can be detected, but the low-amplitude changes require complicated software and extensive processing of 128+ heart beats
Solution Approach 1:
The patent extracts only the essential T-wave amplitude information from the complete ECG signal, focusing specifically on the T-wave portion and its alternans pattern rather than processing the entire 128+ beat ECG record. This extraction approach simplifies the processing requirements while maintaining detection accuracy.
Solution Approach 2:
The patent segments the T-wave analysis into discrete amplitude measurements at specific locations within the T-wave waveform. By breaking down the continuous T-wave signal into measurable segments (peak amplitude, trough amplitude, etc.), the system can process TWA detection more efficiently without requiring complex software to analyze the entire heart beat sequence.
2Measurement precision
If MMA method is used for time domain analysis of T-waves, then TWA can be assessed, but it requires analysis of 128+ heart beats during exercise or high-rate atrial pacing
Solution Approach 1:
The patent applies partial action by analyzing only a subset of heart beats (16-32 beats) rather than the full 128+ beats required by traditional MMA method. This partial analysis approach provides sufficient TWA assessment accuracy while significantly reducing the monitoring time and data processing requirements.
Solution Approach 2:
The patent changes the analysis parameters from traditional time-domain methods to a simplified amplitude-based measurement system. By focusing on specific amplitude parameters of the T-wave rather than comprehensive time-domain characteristics, the system achieves accurate TWA assessment with fewer beats and less processing time.
3Reliability
If TWA monitoring is implemented in implantable medical devices, then patients can be monitored for ventricular arrhythmias, but current methods are not suitable for IMD
Solution Approach 1:
The patent implements self-service by enabling the IMD to autonomously detect TWA and predict arrhythmias using its own integrated sensors and processing capabilities, without requiring external monitoring equipment or complex external software systems. The device performs TWA analysis independently using simplified algorithms suitable for implantable hardware.
Solution Approach 2:
The patent replaces complex software-based TWA analysis systems with a simplified hardware-implemented monitoring approach. By substituting complex computational methods with optimized signal processing circuitry and algorithms tailored for IMD, the system achieves reliable arrhythmia prediction while reducing overall device complexity for implantable applications.
Data Source
AI summary
An implantable medical device and associated method for classifying a patient's risk for arrhythmias by sensing a cardiac electrogram (EGM) signal and selecting a first pair of T-wave signals and a second pair of T-wave signals. A first difference between the two T-wave signals of the first pair is compared to a second difference between the two T-wave signals of the second pair. A T-wave alternans phase reversal is detected in response to comparing the first difference and the second difference, and the patient's arrhythmia risk is classified in response to detecting the phase reversal.